MARKET

TAK

TAK

Takeda Pharm
NYSE
13.07
-0.16
-1.21%
After Hours: 13.05 -0.02 -0.15% 17:13 04/25 EDT
OPEN
13.15
PREV CLOSE
13.23
HIGH
13.19
LOW
13.05
VOLUME
1.70M
TURNOVER
0
52 WEEK HIGH
17.12
52 WEEK LOW
12.90
MARKET CAP
41.01B
P/E (TTM)
32.69
1D
5D
1M
3M
1Y
5Y
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences, Inc. Achieved positive results from its phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with major depressive disorder. The drug may offer several advantages over existing treatment options. The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032. Neurocrine has already received FDA approval for a drug for Huntington's Disease. The company has several catalysts to look forward to.
Seeking Alpha · 6h ago
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 6h ago
Takeda said to have left industry trade group BIO
Japanese drugmaker Takeda said to have left industry trade group BIO. The Biotechnology Innovation Organization claims to be the world's largest biotech trade association. Pfizer's exit from the group last year followed a similar move from the pharma industry's top lobbying group.
Seeking Alpha · 9h ago
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
NASDAQ · 12h ago
Polaris International Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI EAFE Index returning 5.93% for the quarter. The Polaris International Equity Composite returned 3.78% (net of fees), lagging the benchmark. The law of supply and demand played out in copper market prices.
Seeking Alpha · 16h ago
Polaris Global Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter. The Polaris Global Equity Composite returned 6.19% (net of fees), lagging the benchmark. Global portfolio had absolute positive gains across all sectors, led by financials, industrials and consumer discretionary holdings.
Seeking Alpha · 16h ago
New Strong Buy Stocks for April 25th
NASDAQ · 17h ago
Best Income Stocks to Buy for April 25th
NASDAQ · 20h ago
More
About TAK
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Webull offers Takeda Pharmaceutical Co Ltd (ADR) stock information, including NYSE: TAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TAK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TAK stock methods without spending real money on the virtual paper trading platform.